Diastolic heart failure: diagnosis and therapy

  title={Diastolic heart failure: diagnosis and therapy},
  author={Alina Nicoara and Mandisa-Maia Jones-Haywood},
  journal={Current Opinion in Anaesthesiology},
Purpose of review This article focuses on the recent findings in the diagnosis and treatment of diastolic heart failure (DHF) or heart failure with preserved ejection fraction. Recent findings DHF has become the most common form of heart failure in the population. Although diastolic dysfunction still plays a central role, it is now understood that DHF is a very complex clinical entity with heterogeneous pathophysiology and significant contribution from extracardiac comorbidities. Alterations in… 
Left Diastolic Function in Critically Ill Mechanically Ventilated Patients
Echocardiography is one of the most powerful diagnostic and monitoring tools available to the modern intensivist, providing the means to diagnose cardiac systolic or diastolic dysfunction, its underlying cause, and to suggest therapeutic interventions.
Diastolic Ventricular Insufficiency and Use of Anesthetics
The use of anesthetics in diastolic insufficiency should be further studied due to the implications it has at the cardiovascular level when inducing a patient.
The patient with chronic heart failure undergoing surgery
CHF is a source of considerable perioperative morbidity and mortality and in contrast to coronary artery disease, knowledge is very limited and additional research urgently needed.
Diastolic dysfunction in the critically ill patient.
Association with left atrial volume index and long-term prognosis in patients without systolic dysfunction nor atrial fibrillation: an observational study
High-LAVI should be considered a marker of a worse long-term follow-up in patients without systolic dysfunction nor atrial fibrillation, and prevalence of diabetes mellitus, hypertension, and chronic kidney disease, and left ventricular mass index was higher in the high-L AVI group than normal- LAVI group.
Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction
Patients with HFmr EF and HFpEF could benefit from spironolactone treatment, with reduced hospitalizations, BNP levels, improved NYHA-FC, alleviated myocardial fibrosis by decreasing serum PICP in HFmrEF andHFpEF, decreased PIIINP levels and increased 6-MWD only in HFp EF.
Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF)
To diagnose heart failure with preserved ejection fraction (HFpEF), the following three criteria have to be fulfilled: signs and symptoms generally present in heart failure, evidence of diastolic dysfunction and/or relevant structural cardiac alterations, and the presence of a normal LV end-diastolic volume.
Evaluation of the influence of the therapy with fosinopril and zofenopril on the regulatory-adaptive status of patients with diastolic chronic heart failure
Therapy, using fosinopril, in comparison with zofenoprill, more improved RAS (by 66.5%, p) and subjective evaluation of quality of life.
Heart Failure with Preserved Ejection Fraction: Current Diagnostic and Therapeutic Approach
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Stachydrine ameliorates pressure overload-induced diastolic heart failure by suppressing myocardial fibrosis.
The results demonstrate that Sta protects against diastolic heart failure by attenuating myocardial hypertrophy and fibrosis via the TGF-β/Smad pathway.


New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
To maximize the likelihood of identifying effective therapeutics for HF-PEF, lessons learned from the past decade of research should be applied to the design, conduct, and interpretation of future trials.
The pathophysiology of heart failure with preserved ejection fraction
This Review focuses on the current understanding of the pathophysiological mechanisms underlying HFpEF, and how they might be mechanistically related to typical risk factors for HFp EF, including ageing, obesity, and hypertension.
Management of heart failure with preserved ejection fraction: a review.
Heart failure with preserved ejection fraction: refocusing on diastole.
Epidemiology of Right Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction
Improved characterization of the large subset of HFpEF patients with RVD, with and without antecedent pulmonary hypertension may yield critical insights, which inform novel therapeutic interventions.
Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults
While therapies with angiotensin-converting enzyme inhibitors and beta-blockers improve outcomes in SHF, there is currently no such evidence of their benefits in older HFPEF patients.
Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction
Left ventricular hypertrophy or concentric remodeling, LA enlargement, and diastolic dysfunction were present in the majority of patients with HFPEF, and left ventricular mass and LA size were independently associated with an increased risk of morbidity and mortality.
Pharmacotherapy of Heart Failure with Preserved Ejection Fraction
Treatment of heart failure with preserved ejection fraction can be simplified by using three strategies based on applicability: treat precipitating conditions (e.g., hypertension, AF), control symptoms by maintaining euvolemia with diuretics, and avoid therapies that have been shown not to be beneficial unless another compelling indication exists.
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction
The observations bring into question the value of heart rate reduction with ivabradine for improving symptoms in a HFpEF population characterized by exercise limitation.